Why can Kymera (Kymr) be one of the most interesting growth stories in biotechnology?

Kymera Therapeutics Inc. (Nasdaq:ChurchHe is one of The best high beta shares now. The company is currently in charge of optimistic expectations, while the management remains confident in achieving the main clinical end points and biological signs data.

This confidence was visible on September 3, when the company at the Citi “Biopharma conference to school” was presented and made the progress on the target protein deterioration platform (TPD). Kymera Therapeutics Inc.

For context, the deterioration of the target protein (TPD) is a therapeutic approach that uses the protein disposal system in the body to find harmful proteins that cause the disease. Unlike traditional inhibitors, which prevent activity but leave protein intact, TPD treats TPD protein treatments completely, making treatments more effective and longer.

Pressmaster/Shutterstock.com

Data of the first stage of the first stage is expected to start with atopic dermatitis patients later this year, and one of the experiments of the 2b stage, one in dermatitis and one in asthma, is scheduled to start in late 2025 and 2026, respectively. The administration also prepares the manufacture of the third stage of the KT-4621, to ensure the ability to expand at a lower cost.

Kymera Therapeutics Inc. (NASDAQ: KYMR) by developing oral TPD drugs that can provide greater access and comfort compared to injections. The company develops a wide pipeline and works with partners like Sanofi to transfer its programs through clinical trials, although organizational approvals are still an important factor.

The company is a purchase consensus, as all analysts are covered by setting a purchase classification or equivalent. The last of which was to confirm a thunderbolt viewpoint was Brian Cheng from JP Morgan, who reaffirmed the purchase classification on August 21 with a $ 64 goal, which means more than 55 % of the upward trend.

Kymera Therapeutics Inc. (NASDAQ: KYMR) is a biomedical pharmaceutical company that develops protein degradation treatments for immune diseases, infections and cancer.

While we acknowledge the capabilities of Kymr as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 12 large stocks that overlook them with low complications and 10 best stocks for stock wallet for 20 years.

Detection: Nothing. This article was originally published in A monkey from the inside.